PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 22, 20240 citationsOpen Access

Figure S3 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

View Full Paper
AEAlexandria P. EikenASAudrey L. SmithSSSydney A. Skupa

Key Points

Key points are not available for this paper at this time.

Abstract

Figure S3 shows proteomic analysis of SpiD3-treated CLL cells using TMT-labeling.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Eiken et al. (2024) studied this question.

synapsesocial.com/papers/68e68fb4b6db643587616af2https://doi.org/10.1158/2767-9764.25880273
Ask AI
Helpful
Bookmark
Share
View Full Paper